

Nosocomial RSV-related in-hospital mortality in children <5 years: a global case series

Yvette N. Löwensteyn¹, Joukje E. Willemsen¹, Natalie I. Mazur¹, Nienke M. Scheltema¹, Nynke C. J. van Haastregt¹, Amber ten Buuren¹, Ichelle van Roessel¹, Dunja Scheepmaker¹, Harish Nair^{2,3}, Peter M. van de Ven⁴, Louis J. Bont^{1,3}, RSV GOLD study group*

Affiliations

1. Division of Infectious Diseases, Department of Pediatrics, University Medical Centre Utrecht, Utrecht, Netherlands
2. Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
3. Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, The Netherlands
4. Julius Center for Health Sciences and Primary Care, Department of Data Science and Biostatistics, University Medical Centre Utrecht, Utrecht, Netherlands

*RSV GOLD study group collaborators are:

Josep Estrada¹, Angela Gentile², Maria Florencia Lucion², Marcela Echavarría³, Noelia Reyes³, Fernando P. Polack⁴, Mauricio T. Caballero⁴, Annette Alafaci^{5,6}, Nigel Crawford^{5,6}, Jenny Thompson⁶, Warwick Butt^{5,6,7}, Nusrat Homaira⁸, Adam Jaffe⁸, Gemma Saravanos⁹, Philip Britton⁹, Christoph Binder¹⁰, Angelika Berger¹⁰, Bernhard Resch¹¹, Fahmida Chowdhury¹², Md. Ariful Islam¹², Senjuti Saha¹³, Samir Saha¹³, José Gareca Perales¹⁴, Felipe Cotrim de Carvalho¹⁵, Sergio de Andrade Nishioka, on behalf of the Influenza Surveillance Team at the Brazil Ministry of Health^{15,16}, Maria Tereza da Costa Oliveira¹⁷, Carla Cecília de Freitas Lázaro Emediato¹⁷, Heloisa Giamberardino¹⁸, Jane Melissa Webler¹⁸, Regina Grigolli-Cesar^{19,20}, Daniel Jarovsky²¹, Daniela Gregória Bomfim Prado da Silva²¹, Patricia Gomes de Matos Bezerra²², Maria

do Carmo Menezes Bezerra Duarte²², Fernanda de-Paris²³, Márcia Rosane Pires²⁴, Sonia M. Raboni²⁵,
Tani Sagna²⁶, Serge Diagbouga²⁶, Daniel Garros²⁷, Michael Hawkes²⁸, Joanne M. Langley²⁹, Jill Mutch²⁹,
Kirk Leifso³⁰, Shaun K. Morris³¹, Waison Wong³¹, Bosco A. Paes³², Jesse Papenburg³³, Franco Diaz^{34,35},
Rodrigo A. Fasce³⁶, Olga Lopez³⁷, Ting F. Leung³⁸, Wei Su³⁹, Chiang Chun Yuan³⁹, Zhengde Xie⁴⁰,
Junhong Ai⁴⁰, Evelyn Obando Belalcazar⁴¹, Jaime Fernández-Sarmiento⁴², Ledys Izquierdo^{43,44,45}, Rubén
Lasso^{43,44,46}, Rosalba Pardo-Carrero^{43,47}, Pablo Vasquez^{43,44,48}, Eliana Zemanate^{43,44,49}, Srđan Roglić⁵⁰,
Thea K. Fischer⁵¹, Sune Rubak⁵², Mette Holm⁵², Domenica de Mora⁵³, Alfredo Bruno^{53,54}, Jenny Ojeda⁵⁵,
Lida Zamora⁵⁵, Erica Dueger^{56,173}, Terho Heikkinen⁵⁷, Gilles Cambonie⁵⁸, Jean-Christophe Dubus⁵⁹,
Melina Messaoudi⁶⁰, Juliet Bryant⁶⁰, Haoua Tall⁶¹, Bradford D. Gessner⁶¹, Dominique Ploin⁶², Come
Horvat⁶², Nour Hanna⁶³, Christian Vogelberg⁶³, Christoph Härtel⁶⁴, Andrea Streng⁶⁴, Johannes Liese⁶⁴,
Barbara A. Rath^{65,66}, Jürgen Seidenberg⁶⁷, Geeske Stelljes⁶⁷, Evangeline Obodai⁶⁸, John Kofi Odoom⁶⁸,
Irimi Eleftheriou⁶⁹, Maria Tsolia⁶⁹, Vassiliki Papaevangelou⁷⁰, Elpiniki Kartsioni⁷⁰, Tapan Dhole⁷¹,
Sheetal Verma⁷¹, Rashmi Ranjan Das⁷², Ashish Satav⁷³, Agustinus Sutanto⁷⁴, Dario Prais^{75,76}, Orli
Megged⁷⁷, Francesca Tortora⁷⁸, Fabrizio Chiusolo⁷⁸, Giovanni Gabutti⁷⁹, Kazuki Iio⁸⁰, Satoshi Kusuda⁸¹,
Hitoshi Oshitani⁸², Hisato Ito⁸³, Najwa Khuri-Bulos⁸⁴, Loai Saadah⁸⁵, Iman Basheti⁸⁵, Sandra S. Chaves⁸⁶,
Gideon Emukule⁸⁶, Patrick K. Muniyoki^{87,88}, D. James Nokes^{87,89}, Grieven Paul Otieno^{87,89}, Ieva Silina⁹⁰,
Abdulla Alfraij⁹¹, Mohammad Alghounaim⁹², Ghassan Dbaibo⁹³, Rima Hanna-Wakim⁹³, Yoke-Fun
Chan⁹⁴, Jamal I-Ching Sam⁹⁴, Teck-Hock Toh⁹⁵, Jeffrey Soon-Yit Lee⁹⁵, David Pace⁹⁶, Socorro P
Lupisan⁹⁷, Marilla G. Lucero⁹⁷, Daniel E. Noyola⁹⁸, Andreu Comas-García⁹⁸, Túfaria Mussá⁹⁹, Brigitte
Buiteman¹⁰⁰, Diederick E. Grobbee^{101,102}, Rosalie Linssen¹⁰³, Namrata Prasad¹⁰⁴, José F. Sánchez¹⁰⁵, Uzma
Bashir Aamir¹⁰⁶, Qalab Abbas¹⁰⁷, Abdul Momin Kazi¹⁰⁷, Sidra Asif Khan¹⁰⁷, Rodrigo DeAntonio^{108,109},
Xavier Saez-Llorens^{108,110}, Juana del Valle-Mendoza¹¹¹, Wojciech Feleszko¹¹², Karolina Dumycz¹¹², Sara
Cristina de Tavares Ferreira¹¹³, Ana Beatriz de Sousa Pereira Luzio Vaz¹¹³, Mohammed Ahmed Abdullah
Qashnon¹¹⁴, Khalid Alansari^{114,115,116,117}, Eun Hwa Choi¹¹⁸, Yae-Jean Kim¹¹⁹, Eun Lee¹²⁰, Eun-Ae Yang¹²¹,
Hyun Mi Kang¹²¹, Kirill Stolyarov¹²², Thoon Koh Cheng¹²³, Kee Thai Yeo¹²⁴, Chee Fu Yung^{123,125,126},
Stefan Grosek¹²⁷, Marko Pokorn¹²⁷, Cheryl Cohen^{128,129}, Shabir A. Madhi¹²⁹, Michelle J. Groome¹³⁰,

Jocelyn Moyes¹³⁰, Marietjie Venter¹³¹, Adele Visser¹³², Cristina O'Callaghan-Gordo¹³³, Quique Bassat^{133,134,135,136,137}, Cristina Calvo¹³⁸, Xavier Carbonell-Estrany¹³⁹, Francisco J. Elola¹⁴⁰, Manuel Sánchez Luna¹⁴⁰, Rosa Rodriguez Fernandez¹⁴¹, Cristian Launes^{142,143}, Carmen Muñoz-Almagro^{142,143,144}, J.A.A. Sampath Jayaweera¹⁴⁵, Martin W. Weber¹⁴⁶, Joachim Luthander¹⁴⁷, Ulrich Heininger¹⁴⁸, Daniel Trachsel¹⁴⁸, Claudia E. Kuehni¹⁴⁹, Cristina Ardura-Garcia¹⁴⁹, Chia-Yu Chi¹⁵⁰, Hsin Chi¹⁵¹, Shuenn-Nan Chiu¹⁵², Jou-Kou Wang¹⁵², Yhu-Chering Huang¹⁵³, Piyarat Suntarattiwong¹⁵⁴, Somsak Thamthitawat¹⁵⁵, Nasamon Wanlapakorn¹⁵⁶, Aida Borgi¹⁵⁷, Ahmed Ayari¹⁵⁷, Imen Bel Hadj¹⁵⁸, Khadija Boussetta¹⁵⁸, Benan Bayrakci¹⁵⁹, Esra Koçkuzu¹⁵⁹, Muhterem Duyu¹⁶⁰, Sule Gökçe¹⁶¹, Aykut Eşki¹⁶², Tanil Kendirli¹⁶³, Emrah Gün¹⁶³, Edward A. Goka¹⁶⁴, Simon Nadel¹⁶⁵, Marwa Ghazaly¹⁶⁵, Kentigern Thorburn^{166,167}, Paul S. McNamara^{166,167}, Soledad Menta^{168,169}, Nicolás Monteverde^{168,170}, Sebastián González-Dambrauskas^{169,171,172}, Dianna M. Blau¹⁷³, Katherine Horton¹⁷³, Robert F. Breiman¹⁷⁴, Andrea Buchwald¹⁷⁵, Helen Chu¹⁷⁶, Leah Forman¹⁷⁷, Christopher J. Gill¹⁷⁷, Lawrence Mwananyanda¹⁷⁷, Aubree Gordon¹⁷⁸, Natasha Halasa¹⁷⁹, Danielle Hessong¹⁸⁰, Diego Raul Hijano¹⁸¹, Kim J. Allison¹⁸¹, Matthew S. Kelly¹⁸², Veena Kumar¹⁸³, Asuncion Mejias^{184,185}, Octavio Ramilo^{184,185}, Katherine O'Brien, on behalf of the PERCH Study Group¹⁸⁶, Saad B. Omer¹⁸⁷, Thyar Ravindranath¹⁸⁸, Steven L. Shein¹⁸⁹, Ananya Parlapalli¹⁸⁹, Eric A F Simões¹⁹⁰, Michael C Spaeder¹⁹¹, Pham Thi Minh Hong¹⁹², Tran Anh Tuan¹⁹³, Mohammed Al Amad¹⁹⁴, Abdul Wahed Al Serouri¹⁹⁴

1. SAAS, Escaldes Engordany, Andorra
2. Department of Epidemiology, Ricardo Gutiérrez Children's Hospital, Buenos Aires, Argentina
3. CEMIC University Hospital, Buenos Aires, Argentina
4. Fundación Infant, Buenos Aires, Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.
5. Murdoch Children's Research Institute, Melbourne, Australia
6. The Royal Children's Hospital, Melbourne, Australia

7. Department of Paediatrics, University of Melbourne, Melbourne, Australia
8. University of New South Wales, Sydney, Australia
9. The University of Sydney Children's Hospital Westmead Clinical School, Sydney, Australia
10. Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University Vienna, Vienna, Austria
11. Medical University of Graz, Graz, Austria
12. Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
13. Dhaka Shishu Hospital, Dhaka, Bangladesh
14. Centro de Pediatria Especializada "CRECER", Santa Cruz de la Sierra, Bolivia
15. Department of Transmissible Diseases, Ministry of Health, Brasília, Brazil
16. Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brazil
17. Health Secretariat of the City of Belo Horizonte, Belo Horizonte, Brazil
18. Hospital Pequeno Principe, Curitiba, Brazil
19. Hospital Infantil Sabará, São Paulo, Brazil
20. Red Colaborativa Pediátrica de Latinoamérica (LAREd Network), São Paulo, Brazil
21. Santa Casa de São Paulo, São Paulo, Brazil
22. Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
23. Transplant Immunology and Personalized Medicine Unit, Laboratory Diagnostics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
24. Infection Control Commission, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
25. Universidade Federal do Paraná, Paraná, Brazil
26. Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso, Burkina Faso
27. Stollery Children's Hospital, Edmonton, Canada

28. University of Alberta, Alberta, Canada
29. Canadian Center for Vaccinology (Dalhousie University, IWK Health and NS Health),
Halifax, Canada
30. Kingston General Hospital, Kingston, Canada
31. Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Canada
32. Neonatal Division, Department of Pediatrics, McMaster University, Hamilton, Canada
33. Montreal Children's Hospital, McGill University Health Centre, Montreal, Canada
34. Hospital La Florida Dra. Eloísa Díaz, Santiago, Chile
35. Red Colaborativa Pediátrica de Latinoamérica (LAREd Network), Santiago, Chile
36. Public Health Institute, Santiago, Chile
37. Hospital Dr. Ernesto Torres Galdames, Iquique, Chile
38. Department of Paediatrics, Faculty of Medicine and Chinese University of Hong Kong-
University Medical Center Utrecht Joint Research Laboratory of Respiratory Virus
and Immunobiology, Chinese University of Hong Kong, Hong Kong, China
39. CanAm International Medical Center, Guang Zhou, China
40. Beijing Children Hospital, Beijing, China
41. Instituto Roosevelt, Bogotá, Colombia
42. Universidad de La Sabana, Fundación Cardioinfantil-Instituto de Cardiología, Bogotá,
Colombia
43. Red Colaborativa Pediátrica de Latinoamérica (LAREd Network), Bogotá, Colombia
44. BACON, Bogotá, Colombia
45. Hospital Militar Central, Bogotá, Colombia
46. Fundación Valle de Lili, Cali, Colombia
47. Clínica Infantil Colsubsidio, Bogotá, Colombia
48. Hospital de San José, Bogotá, Colombia
49. Hospital Susana López de Valencia E.S.E., Popayán, Colombia

50. Department of Paediatric Infectious Diseases, University Hospital for Infectious Diseases, Zagreb, Croatia
51. University of Copenhagen, Institute of Public Health, Copenhagen, Denmark
52. Danish Center of Pediatric Pulmonology and Allergology, Department of Pediatrics and Adolescents Medicine, Aarhus University Hospital, Aarhus, Denmark
53. Instituto Nacional de Investigacion en Salud Publica, Guayaquil, Ecuador
54. Universidad Agraria del Ecuador, Guayaquil, Ecuador
55. Ministerio de Salud Pública del Ecuador, MSP, Quito, Ecuador
56. Global Disease Detection and Response Program, US Naval Medical Research Unit No. 3, Cairo, Egypt
57. Turku University Hospital and University of Turku, Turku, Finland
58. Montpellier University Hospital Center, Montpellier, France
59. CHU Timone-Enfants, Marseille, France
60. Emerging Pathogens Laboratory - Fondation Merieux, Lyon-Gerland, France
61. Agence de Medecine Preventive, Paris, France; currently with Pfizer, Inc, New York, NY, USA
62. Services de Reanimation et d'Urgences Pediatriques, Hopital Femme Mere Enfant des Hospices Civils de Lyon, Lyon, France
63. Pediatric Department, University Hospital Carl Gustav Carus, Dresden, Germany
64. Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany
65. Vienna Vaccine Safety Initiative, Berlin, Germany
66. University of Bourgogne-Franche-Comté, Besançon, France.
67. University Hospital for Children, Klinikum Oldenburg AöR, Oldenburg, Germany
68. Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana
69. Children's Hospital `P.& A.Kyriakou`, Athens, Greece

70. Third Department of Pediatrics, National and Kapodistrian University of Athen,
ATTIKON Hospital, Athens, Greece
71. King George's Medical University, Lucknow, India
72. All India Institute of Medical Sciences Bhubaneswar (AIIMS), Bhubaneswar, India
73. MAHAN trust (Mahatma Ghandi Tribal Hospital), Kadhava, India
74. West Nusa Tenggara Provincial Government, Lombok, Indonesia
75. Schneider Children`s Medical Center of Israel, Petah Tikva, Israel
76. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
77. Shaare Zedek Medical Center, Jerusalem, Israel
78. Bambino Gesù Children's Hospital, Rome, Italy
79. University of Ferrara, Department of Medical Sciences, Section of Public Health
Medicine, Ferrara, Italy
80. Tokyo Metropolitan Children`s Medical Center, Tokyo, Japan
81. Kyorin University, Tokyo, Japan
82. Department of Virology, Tohoku University Graduate School of Medicine, Sendai,
Japan
83. Department of Pediatrics, Nantan General Hospital, Ueno, Yagichoyagi, Nantan-shi,
Kyoto, Japan
84. Department of Pediatrics, University of Jordan, Amman, Jordan
85. Applied Science Private University, Amman, Jordan
86. Centers for Disease Control and Prevention (CDC), Influenza Program, Nairobi, Kenya
87. KEMRI Welcome Trust Research Programme, Kilifi, Kenya
88. Department of Nursing Sciences, Pwani University, Kilifi, Kenya
89. University of Warwick, Coventry, UK
90. Children's Clinical University Hospital, Riga, Latvia

91. Pediatric Intensive Care Unit, Department of Pediatrics, Farwaniya Hospital, Kuwait City, Kuwait
92. Department of Pediatrics, Amiri Hospital, Kuwait City, Kuwait
93. American University of Beirut, Beirut, Lebanon
94. University of Malaya, Kuala Lumpur, Malaysia
95. Clinical Research Centre, Sibuh Hospital, Ministry of Health Malaysia, Sibuh, Sarawak, Malaysia
96. Mater Dei Hospital, Msida, Malta
97. Research Institute for Tropical Medicine, Alabang Muntinlupa City, Metro Manila Philippines
98. Universidad Autonoma de San Luis Potosi, San Luis Potosi, Mexico
99. Universidade Eduardo Mondlane, Maputo, Mozambique
100. University Medical Center Utrecht, Utrecht, Netherlands
101. Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands
102. Julius Clinical Science, Zeist, Netherlands
103. Pediatric Intensive Care Unit, Emma Children's Hospital Amsterdam UMC, Amsterdam, The Netherlands
104. Institute of Environmental Science and Research, Auckland, New Zealand
105. Department of Medicine, Hospital Infantil Manuel de Jesus Rivera, Managua, Nicaragua
106. Department of Virology, National Institute of Health, Islamabad, Pakistan
107. Department of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan
108. Sistema Nacional de Investigación-Secretaría Nacional de Ciencia, Tecnología e Innovación (SNI-SENACYT), Panama City, Panama
109. Centro de Vacunación e Investigación CEVAXIN, Panama City, Panama

110. Hospital Del Niño Dr. José Renán Esquivel, Departamento de Infectología, Panama City, Panama
111. School of Medicine, Research Center of the Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas, Lima, Peru
112. Department of Pediatric Respiratory Diseases and Allergy, Medical University of Warsaw, Warsaw, Poland
113. Department of Pediatrics Hospital Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal
114. Department of Pediatrics, Division of Pediatric Emergency Medicine, Hamad Medical Corporation, Doha, Qatar
115. Department of Emergency Medicine, Sidra Medicine, Doha, Qatar
116. Weill Cornell Medicine, Doha, Qatar
117. Clinical Department, College of Medicine, QU Health, Qatar University, Doha, Qatar
118. Seoul National University College of Medicine, Seoul, South Korea
119. Sungkyunkwan University School of Medicine, Seoul, South Korea
120. Chonnam National University Hospital, Gwangju, South Korea
121. Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, South Korea
122. WHO Russian Federation, Leningrad, Russian Federation
123. Infectious Diseases Service, KK Women's and Children's Hospital, Singapore
124. Department of Neonatology, KK Women's & Children's Hospital, Singapore, Singapore
125. Duke-NUS Medical School, Singapore, Singapore
126. Lee Kong Chian School of Medicine, Imperial College, NTU Singapore
127. UMC Ljubljana, Ljubljana, Slovenia

128. School of Public Health, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa
129. Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa
130. Medical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa
131. University of Pretoria, Pretoria, South Africa
132. Department of Philosophy, Practical and Systematic Theology, School of Humanities, University of South Africa, Pretoria, South Africa
133. ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain
134. ICREA, Catalan Institution for Research and Advanced Studies, Barcelona, Spain
135. Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain
136. Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique
137. Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
138. Hospital La Paz. IdiPAZ Foundation, CIBER Infectious Diseases (ISCIII), Translational Research Network in Pediatric Infectious Diseases (RITIP), Madrid, Spain
139. IRIS group Coordinator, Hospital Clinic, Institut d'Investigacions Biomediques August Pi Suñer (IDIBAPS), Barcelona, Spain
140. Fundación Instituto para la Mejora de la Asistencia Sanitaria / Research Institute Gregorio Marañón, Madrid, Spain
141. Hospital Gregorio Marañón, Madrid, Spain
142. Institut de Recerca Pediàtrica Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain

143. Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP),
Madrid, Spain
144. Department of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain
145. Department of Microbiology, Faculty of Medical and Allied Sciences, Rajarata
University of Sri Lanka, Saliyapura, Sri Lanka
146. Department of Child and Adolescent Health and Development, World Health
Organization, Geneva, Switzerland
147. Astrid Lindgren Children's Hospital, Karolinska University Hospital, Solna, Sweden
148. University of Basel Children's Hospital, Basel, Switzerland
149. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
150. National Health Research Institutes, Zhunan, Taiwan
151. Department of Pediatric Infectious Disease, MacKay Children's Hospital, Taipei, Taiwan
152. Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
153. Chang Gung Memorial Hospital, Taoyuan City, Taiwan
154. Queen Sirikit National Institute of Child Health, Bangkok, Thailand
155. Division of Global Health Protection, Thailand Ministry of Public Health-US Centers
for Disease Control and Prevention Collaboration, Nonthaburi, Thailand
156. Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
157. Hôpital d'enfants Béchir Hamza , Tunis, Tunisia
158. Bechir Hamza Children's Hospital, Tunis, Tunisia
159. Department of Pediatric Intensive Care Medicine, Hacettepe University. Life Support
Practice and Research Center, Ankara, Turkey
160. Istanbul Medeniyet University, Goztepe Training and Research Hospital, Istanbul,
Turkey
161. Ege University Medical Faculty, Izmir, Turkey
162. Ege University Children's Hospital, Izmir, Turkey

163. Department of Pediatric Intensive Care, Ankara University School of Medicine, Ankara, Turkey
164. School of Health and Related Research, University of Sheffield, Sheffield, UK
165. Saint Mary's Hospital, London, UK
166. Department of Paediatric Intensive Care, Alder Hey Children's Hospital, Liverpool, UK
167. Department of Child Health (University of Liverpool), Institute in the Park, Alder Hey Children's Hospital, Liverpool, UK
168. Hospital Tacuarembó, Tacuarembó, Uruguay
169. Red Colaborativa Pediátrica de Latinoamérica (LARed Network), Montevideo, Uruguay
170. Médica Uruguaya, Montevideo, Uruguay
171. Cuidados Intensivos Pediátricos Especializados (CIPE), Casa de Galicia, Montevideo, Uruguay
172. Facultad de Medicina, Unidad de Cuidados Intensivos de Niños del Centro Hospitalario Pereira Rossell (UCIN-CHPR), Universidad de la República, Montevideo, Uruguay
173. Centers for Disease Control (CDC) and Prevention, Atlanta, USA
174. Emory University, Global Health Institute, Atlanta, USA
175. University of Maryland Baltimore, Baltimore, USA
176. University of Washington, Seattle, USA
177. Boston University School of Public Health, Boston, USA
178. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, USA
179. Vanderbilt University Medical Center, Nashville, USA
180. Children's Hospital Colorado, Colorado, USA
181. St Jude Children's Research Hospital, Memphis, USA
182. Division of Pediatric Infectious Diseases, Duke University, Durham, USA

183. AstraZeneca, Hershey, USA
184. Department of Pediatrics, Division of Infectious Diseases, Ohio State University, Columbus, USA
185. Center for Vaccines and Immunity at Nationwide Children's Hospital, Ohio State University, Columbus, USA
186. International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
187. Yale Institute for Global Health, New Haven, USA
188. Morgan Stanley Children's Hospital of New York-Presbyterian, New York, USA
189. Rainbow Babies and Children's Hospital, Cleveland, USA
190. Department of Pediatrics and Center for Global Health, University of Colorado, Aurora, USA
191. Division of Pediatric Critical Care, University of Virginia School of Medicine, Charlottesville, USA
192. Department of Pediatrics, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh city, and Respiratory Department, Children's Hospital No2, Ho Chi Minh city, Vietnam
193. Respiratory department, Children's Hospital No1, Ho Chi Minh City, Vietnam
194. Yemen-FETP, Sana'a, Yemen

Corresponding author:

Louis J. Bont, MD, PhD

Department of Paediatric Immunology and Infectious Diseases

Wilhelmina Children's Hospital/University Medical Centre Utrecht

Room KC.02.066, PO Box 85090, 3508 AB, Utrecht, The Netherlands

E-mail: l.bont@umcutrecht.nl. Tel: +31 88 755 55 55.

Alternate author:

Yvette N. Löwensteyn, MD, PhD candidate

Department of Paediatric Immunology and Infectious Diseases

Wilhelmina Children's Hospital/University Medical Centre Utrecht

Room KC.02.066, PO Box 85090, 3508 AB, Utrecht, The Netherlands

E-mail: y.n.loewensteyn@umcutrecht.nl. Tel: +31 88 755 55 55.

Keywords: Respiratory syncytial virus; nosocomial infection; community-acquired infection; child mortality; global health

Running title

Nosocomial RSV-related mortality

Key points

- The proportion of reported nosocomial RSV-related deaths is substantially lower in lower-middle-income countries than in upper-middle-income countries and high-income countries (12% vs 18% and 26%, respectively).
- The majority of nosocomial RSV-related deaths can be prevented by infant-targeted immunization strategies as more than half were younger than 6 months of age.

Word count manuscript: 2430/3000

Word count abstract: 254/255

References: 27/40

ABSTRACT

Background

According to the World Health Organization the global burden of nosocomial infections is poorly characterized as surveillance systems for nosocomial infection are lacking. Nosocomial infections occur at higher rates in low- and lower-middle-income countries (LMICs) than in high-income countries (HICs). Current global RSV burden estimates are largely based on community-acquired disease. We aimed to characterize children with nosocomial RSV-related mortality and to understand the potential impact of RSV immunization strategies.

Methods

RSV GOLD is a global registry of children younger than 5 years who died with laboratory-confirmed RSV infection. We compared clinical and demographic characteristics of children with nosocomial and community-acquired RSV in-hospital mortality.

Results

We included 231 nosocomial and 931 community-acquired RSV-related in-hospital deaths from 65 countries. Median age at death was similar for both groups (5.4 vs 6 months). As expected, a higher proportion of children with nosocomial infection had comorbidities (87% vs 57%; $p < 0.001$) or was born preterm (46% vs 24%; $p < 0.001$) than children with community-acquired infection. The proportion of nosocomial deaths among all RSV deaths was lower in LMICs than in upper-middle-income countries (UMICs) and HICs (12% vs 18% and 26%, respectively).

Conclusions

This is the first global case series of children dying with nosocomial RSV infection. Future infant-targeted immunization strategies can prevent the majority of nosocomial RSV-related deaths. Although nosocomial RSV deaths are expected to occur at highest rates in LMICs, the number of reported nosocomial RSV

deaths was low in these countries. Hospital-based surveillance is needed to capture the full burden of nosocomial RSV mortality in LMICs.

INTRODUCTION

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) and LRTI-related death in young children. In 2015, the overall RSV mortality burden was estimated at 118200 annual deaths in children younger than 5 years of age worldwide.[1] These global burden estimates are largely based on community-acquired RSV-related deaths due to the paucity of data on healthcare-associated or nosocomial RSV-related mortality. According to the World Health Organization (WHO) the burden of nosocomial infections is poorly characterized in LMICs as surveillance systems are lacking.[2] Nevertheless, available data show that the burden of nosocomial infections is significantly higher in low- and middle-income countries (LMICs) compared to high-income countries (HICs).[3] Furthermore, RSV has been reported as the most important viral cause of nosocomial LRTI in children.[4-7]

The proportional contribution of nosocomial RSV mortality to the global RSV mortality burden is expected to be substantial, as nosocomial RSV infection is generally more severe than community-acquired RSV infection.[8-10] Currently, several RSV vaccine candidates and monoclonal antibodies are in late phase clinical development.[11] To identify vaccine target populations and to estimate the potential impact of these RSV prevention strategies, healthcare policy makers require information on the characteristics of children with life-threatening RSV infection including those with nosocomial RSV infection. However, previous reports of pediatric nosocomial RSV-related deaths are from single centres and not large enough (number of deaths ranging between 1-21)[12] to understand the demographic and clinical characteristics of children dying with nosocomial RSV infection globally.

Through our global RSV mortality registry, we aimed to describe demographic and clinical characteristics of children younger than 5 years of age dying in the hospital with laboratory-confirmed nosocomial RSV infection.

METHODS

Study design and patients

The RSV GOLD study is an ongoing global online mortality registry that includes individual patient data of children younger than 5 years of age who died with RSV infection. The first study results, published in 2017, included only community-acquired, in-hospital deaths.[13] Since then, the registry has been extended to also include nosocomial and out-of-hospital pediatric RSV-related deaths from January 1, 1995 onwards.[14] To obtain nosocomial RSV-related mortality patient data, we performed a systematic search in PubMed using the following search terms: “RSV” or “bronchiolitis” combined with “healthcare-associated pneumonia”, “nosocomial”, “community-acquired”, “in-hospital”, “hospital-borne”, or “cross-infection” (Supplemental Table 1). We invited authors to share patient data until July 31st, 2021 using a link to our electronic data capture platform Research Online.[15] We included published and unpublished data of children aged 0-59 months who had died with laboratory-confirmed RSV infection in the hospital between January 1, 1995 and July 31st, 2021. We excluded children for whom it was unknown where RSV infection had been acquired (in-community or in-hospital [n=489]). We collected demographic and clinical characteristics using an online questionnaire within Research Online.

Definitions

We categorized country of origin as LMIC (LIC and LMIC combined), upper-middle income country (UMIC), or HIC according to the World Bank classifications for 2021.[16] We defined nosocomial RSV infection as a positive laboratory-confirmed RSV test in combination with a ≥ 48 -hour timeframe between hospital admission and onset of respiratory symptoms, and as reported by the RSV GOLD collaborator. Length of hospital stay was defined as the duration of the hospital admission in days starting from the beginning of respiratory symptoms. Comorbidity was defined as the presence of at least one underlying disease. Prematurity was defined as gestational age less than 37 weeks. If data for comorbidities or

prematurity were not reported (n=17), we assumed that the children were otherwise health and born at term. If data for location of death were missing (n=3), we assumed that the death had occurred in hospital.

Nosocomial RSV infection and community-acquired RSV-related mortality

We compared the demographic and clinical characteristics of children with nosocomial RSV-related in-hospital death and those with community-acquired RSV-related in-hospital death, including previously published RSV GOLD data.[13, 17] We analyzed the data separately for different income groups and calculated for each income group the odds ratios and 95% confidence interval (CI) for the presence of demographic and clinical characteristics in children with hospital-acquired RSV relative to children with community-acquired RSV.

Sensitivity analyses

We excluded deaths with missing data for comorbidities or prematurity and compared demographic and clinical characteristics. We also analyzed the age distribution for nosocomial RSV deaths from LMICs after excluding deaths collected from a post-mortem study conducted in Zambia in which only children aged <6 months were included (n=12).[18]

Ethical approval

The institutional research board of the University Medical Centre Utrecht waived the requirement for parental consent as only de-identified secondary patient data are used in the RSV GOLD study. Collaborators sharing data were encouraged to adhere to local site regulations for ethics approval. Where required, local ethical approval was obtained.

Statistical analysis

We present descriptive statistics for all variables. For continuous variables we report the median with interquartile range (IQR); for categorical variables we report the frequency and proportion. We used the

Fisher's exact test to determine statistical significance between groups for dichotomous parameters and the Mann-Whitney-U test for all continuous parameters. We applied the Bonferroni correction for multiple testing between World Bank Income groups. All statistical analyses were performed with SPSS (version 21.0; IBM Corp, Armonk, NY). The forest plot with odds ratios and 95% CIs was made in R version 4.0.3.

RESULTS

We included a total of 231 nosocomial RSV-related deaths from 38 countries (Figures 1-2, Supplemental Table 3) of which 80 deaths were identified through the literature search (Supplemental Tables 1-2) and 188 comprised unpublished reports shared by collaborators. The 231 deaths accounted for 20% of all deaths reported to the RSV GOLD registry with available data on where RSV infection was acquired. The majority (n=123; 53%) of reported deaths were from HICs. The proportion of reported nosocomial deaths among all RSV-related in-hospital deaths was substantially lower in LMICs (12%) than in UMICs (18%, $p=0.03$) or HICs (26%, $p<0.001$).

Clinical and demographic characteristics of children with nosocomial RSV-related mortality

The vast majority of children with nosocomial RSV-related death had one or more comorbidities (n=202, 87.4%) as expected. Congenital heart disease was the most prevalent comorbidity occurring in almost half (n=96, 41.6%) of all nosocomial deaths. In total, 106 (45.9%) children had been born prematurely. Median age at time of death was 5.4 (IQR: 2.5-12.1) months. Half of the deaths (51.9%) occurred within the first 6 months of life (Table 1, Figure 3).

Nosocomial RSV-related mortality analyzed by World Bank Income group

Children from LMICs were younger at time of death than children from UMICs (1.5 vs. 5 months, $p=0.003$) and HICs (1.5 vs. 7 months, $p<0.001$). More children from LMICs died during the neonatal

period (40.6%) than children from UMICs (3.9%) and HICs (1.6%), $p<0.001$. Furthermore, compared to HICs, children from LMICs were more often born prematurely (68.8% vs. 43.1%, $p=0.01$), had a shorter hospital stay (7 days vs. 37 days, $p<0.001$) and were less often mechanically ventilated (46.9% vs. 85.2%, $p<0.001$). Additional characteristics for children analyzed by income group are included in Supplemental Table 4.

Nosocomial versus community-acquired RSV-related mortality

The proportion of preterm children was higher among children with nosocomial RSV infection compared to children with community-acquired RSV infection (45.9% vs. 24.2%, $p<0.001$). Likewise, a higher proportion of children with nosocomial RSV infection had at least one comorbidity (87.4% vs. 56.6%, $p<0.001$). Age at death was similar for both groups. We compared both nosocomial and community-acquired deaths for each income group separately to rule out sampling bias by underrepresentation of deaths from LMICs. In this analysis, children from LMICs with nosocomial RSV-related death were younger than children with community-acquired death (1.5 vs 5.0 months, $p=0.002$). For children from UMICs and HICs, age at death was similar (Supplemental Table 5-7). The odds ratios and 95% CIs for the presence of demographic and clinical characteristics in children with nosocomial vs. community-acquired RSV-related mortality in all included children and stratified by income group are presented in Supplemental Figure 1.

Sensitivity analyses

When analyzing the data after excluding children with missing data for comorbidity or prematurity ($n=19$ for nosocomial RSV deaths; $n=231$ for community-acquired RSV deaths), our findings did not change (Supplemental Table 8). After excluding deaths collected from the post-mortem study in Zambia ($n=12$), median age increased to 5 months for nosocomial deaths from LMICs.

DISCUSSION

Globally, RSV is a major cause of child mortality. Current RSV mortality burden estimates are largely based on community-acquired RSV-infections. We report the first global case series characterizing children younger than 5 years who died with nosocomial RSV infection. We observed that nosocomial RSV-related deaths accounted for 20% of all in-hospital RSV deaths reported to the RSV GOLD registry. This proportion indicates that nosocomial RSV-related deaths substantially contribute to the global burden of RSV-related child mortality.

While literature indicates that nosocomial infections generally occur at higher rates in LMICs than in HICs[3], the small number of nosocomial deaths from LMICs suggests these cases are underreported in LMICs. For example, data from the Zambia Pertussis Infant Mortality Estimation Study (ZPRIME) showed that 32% of RSV deaths in a tertiary referral hospital in Lusaka, Zambia, were due to nosocomial RSV infection.[18] The low number of LMIC nosocomial deaths in the RSV GOLD registry may be explained by sub-optimal testing capacity and a lack of active RSV surveillance systems and general underreporting of nosocomial deaths. Furthermore, ascertainment bias could play a role as data from LMICs mainly result from RSV studies that usually do not include nosocomial RSV deaths whereas data from HICs may also result from routine testing.

We found that age at death was similar for children with nosocomial and community-acquired RSV-related death. To our knowledge, there are no other studies available reporting on age in deceased pediatric patients with nosocomial and community-acquired infection. Two prospective studies from Vietnam and Germany report a younger age in pediatric patients with nosocomial RSV infection[8, 19], while studies from Brazil and the UK report an older age for nosocomial RSV patients (although the age difference was no longer significant when comparing comorbidity-matched controls in the UK study).[12, 20] More than half of reported nosocomial deaths were in children younger than 6 months at time of

death. This age distribution indicates that infant-targeted RSV immunization strategies will prevent a large part of nosocomial RSV-related mortality globally.

Most children with nosocomial RSV-related mortality had, as expected, at least one comorbidity. Most frequently reported comorbidities were congenital heart disease, certain genetic disorders such as trisomy 21 (Down syndrome), and neurological disease. These findings are in line with findings from other studies that identified congenital heart disease, Down syndrome, immunodeficiency[6], and prematurity[8] as risk factors for acquiring RSV infection in the hospital. In a Canadian study, children with nosocomial RSV infection were more likely to have preexisting risk factors for severe disease including prematurity, immunodeficiency, lung disease, or heart disease, and stayed longer in the hospital than children with community-acquired RSV infection, which is comparable to our results.[9] In our registry, there were more premature infants with RSV-related nosocomial death from LMICs (69%) compared to UMICs (41%) or HICs (43%) and less children with comorbidity (69%) compared to children from HICs (96%). Possibly, in LMICs, children who are born preterm in the hospital may acquire nosocomial RSV infection and subsequently die at a younger age before comorbidities are identified. This contrasts with HICs, where children who die with RSV generally have comorbidities and are susceptible to severe nosocomial infection at an older age from repeated exposure to RSV through multiple hospital admissions. Taken together, differences in clinical characteristics may partially be explained by differences in quality of healthcare.

This study has several limitations inherent to retrospective data collection. First, the majority of the reported deaths were from UMICs and HICs while LMICs represent more than 75% of the global pediatric population and have a higher prevalence of nosocomial infections.[21] Second, since not all authors responded or shared data, we missed at least 24 deaths reported in the literature. All but three missed published deaths were from UMICs or HICs and median age at death was one month (information on age available for seven deaths). Third, authors employed variable definitions for nosocomial infection

(time interval between admission and start of respiratory symptoms ranging from 48 hours to 7 days) which may have over- or underestimated our results. Although we did not collect these definitions, we checked for each hospital-acquired RSV mortality case whether the time interval between admission and symptoms was at least 48 hours. Furthermore, there were no studies that involved surveillance on nosocomial post-discharge deaths. The actual burden of nosocomial RSV-related mortality may therefore be higher than reported in the literature. Reporting bias could also lead to an underestimation of nosocomial RSV-related mortality as RSV outbreaks may not always be reported or detected by hospitals. Fourth, we did not collect information on the reason for hospital admission before the child acquired RSV, nor on location where RSV infection was acquired (ward or intensive care unit). Last, retrospective data vary in quality and completeness, although we attempted to limit the impact of this methodological weakness with data quality checks and direct verification with collaborators.

Our study has clinical implications. RSV is one of the major causes of nosocomial outbreaks in pediatric wards as it is highly transmissible, with a basic reproduction number - the number of secondary infections caused by one infected child - estimated between 1-9.[22] RSV is spread through direct contact or large droplet transmission but not through aerosol transmission.[23] Nosocomial RSV infections are associated with increased hospital costs due to prolonged hospitalization and extra interventions, and with high morbidity and mortality.[24, 25] Our results show that nosocomial RSV-related deaths may substantially contribute to the global burden of RSV-related child mortality. More than half of reported deaths were younger than 6 months and may have been prevented by infant-targeted RSV immunization strategies such as long-acting monoclonal antibodies. While the global community awaits market-approval and implementation of maternal vaccination and introduction of nirsevimab, a highly potent long-acting antibody that recently met the primary endpoint in a phase-III trial[11], infection-control measures remain of major importance to prevent nosocomial infections. Although high-quality evidence is lacking, multicomponent control strategies appear broadly successful.[26] Strict infection control measures

including hand hygiene and the use of protective equipment (goggles, gloves, gowns, masks), can reduce nosocomial infection rates by 39-76%.[27]

In conclusion, this study provides insight into characteristics of global nosocomial RSV-related mortality in young children. Prospective studies and hospital-based surveillance are needed to demonstrate the magnitude of the nosocomial RSV burden in LMICs. Infection control measures, in particular hand hygiene, remain of significant importance to prevent nosocomial infections in pediatric wards worldwide.

NOTES

Funding

This work was supported by the Bill & Melinda Gates Foundation [OPP1148988].

Potential conflicts of interest

LJB has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU has received major funding (>€100,000 per industrial partner) for investigator-initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation, Nutricia (Danone) and MeMed Diagnostics. UMCU has received major cash or in kind funding as part of the public private partnership IMI-funded RESCEU project from GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in the INFORM study sponsored by MedImmune. UMCU has received minor funding for participation in trials by Regeneron and Janssen from 2015-2017 (total annual estimate less than €20,000). UMCU received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Pfizer, Janssen (total annual estimate less than €20,000). LJB is the founding chairman of the ReSViNET Foundation. HN has received grants from Innovative medicines initiative and Pfizer. He has received honorarium from Abbvie, Sanofi, ReViral, Janssen and Novavax.

Acknowledgements

We are grateful to the collaborators of the RSV GOLD study group for sharing data with the RSV GOLD registry. We thank Dr. Sheikh Wasik Rahman, Mr. Shuborno Islam, Ms. Naito Kanon, Prof. Nawshad Ahmed, Dr. Rubana Sultana Aflatun and Dr. Sohel Mahmud of the Child Health Research Foundation for their intellectual, laboratory, and technical assistance with compiling the RSV dataset of Bangladesh. We thank Prachi Vora and Padmini Srikantiah for their scientific advice. Furthermore, we thank Femke

Vernooij from the RSV GOLD student operations team for her help with data analyses.


REFERENCES

1. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *The Lancet* **2017**; 390(10098): 946-58.
2. World Health Organization. Health-care associated infections. Fact sheet. Available from: https://www.who.int/gpsc/country_work/gpsc_ccisc_fact_sheet_en.pdf. Accessed January 5 2022.
3. Allegranzi B, Nejad SB, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. *The Lancet* **2011**; 377(9761): 228-41.
4. Hall CB. Nosocomial Respiratory Syncytial Virus Infections: The "Cold War" Has Not Ended. *Clinical Infectious Diseases* **2000**; 31: 590-6.
5. Spaeder MC, Fackler JC. Hospital-acquired viral infection increases mortality in children with severe viral respiratory infection. *Pediatr Crit Care Med* **2011**; 12(6): e317-21.
6. Sampath Jayaweera JAA, Reyes M. Childhood nosocomial viral acute respiratory tract infections in teaching hospital Anuradhapura, Sri Lanka. *BMC Res Notes* **2019**; 12(1): 581.
7. Ford-Jones EL, Mindorff, C.M., Langley, J.M., Allen, U., Navas, L., Patrick, M.L., Milner, R., Gold, R. Epidemiologic study of 4684 hospital-acquired infections in pediatric patients. *Pediatr Infect Dis J* **1989**; 8(10).
8. Simon A, Muller A, Khurana K, et al. Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection--results from a prospective multicenter German surveillance study. *Int J Hyg Environ Health* **2008**; 211(3-4): 241-50.
9. Langley JML, J.C.; Wang, E.E.L.; Law, B.J.; MacDonald, N.E.; Mitchell, I.; Stephens, D.; McDonald, J.; Boucher, F.D.; Dobson, S. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: A pediatric investigators collaborative network on infections in Canada study. *Pediatrics* **1997**; 100.
10. Lee YI, Peng CC, Chiu NC, Huang DT, Huang FY, Chi H. Risk factors associated with death in patients with severe respiratory syncytial virus infection. *J Microbiol Immunol Infect* **2016**; 49(5): 737-42.
11. Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants. Available from: <https://www.astrazeneca.com/media-centre/press-releases/2021/nirsevimab-phase-iii-trial-met-primary-endpoint.html>. Accessed May 10 2021.
12. Thorburn K, Eisenhut, M.; Riordan, A. Mortality and morbidity of nosocomial respiratory syncytial virus (RSV) infection in ventilated children - A ten year perspective. *Minerva Anestesiologica* **2012**; 78(7).
13. Scheltema NM, Gentile A, Lucion F, et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. *The Lancet Global Health* **2017**; 5(10): e984-e91.
14. Mazur NI, Löwensteyn YN, Willemsen JE, et al. Global Respiratory Syncytial Virus-Related Infant Community Deaths. *Clinical Infectious Diseases* **2021**; 73(Supplement_3): S229-S37.

15. Research Online. Available at: <https://www.researchonline.info/en-us/>. Accessed June 5 2021.
16. Bank TW. World Bank Country and Lending Groups. Available at: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>. Accessed May 12 2021.
17. Löwensteyn YN, Phijffer E, Simons JVL, et al. Respiratory Syncytial Virus-related Death in Children With Down Syndrome: The RSV GOLD Study. *Pediatr Infect Dis J* **2020**.
18. Forman LS, Macleod W, Mwananyanda L, et al. Association of Respiratory Syncytial Virus Infection and Underlying Risk Factors for Death Among Young Infants Who Died at University Teaching Hospital, Lusaka Zambia. *Clin Infect Dis* **2021**; 73(Supplement_3): S180-S6.
19. Tuan TA, Thanh TT, Hai N, et al. Characterization of hospital and community-acquired respiratory syncytial virus in children with severe lower respiratory tract infections in Ho Chi Minh City, Vietnam, 2010. *Influenza Other Respir Viruses* **2015**; 9(3): 110-9.
20. De-Paris FB, C.; de Souza Nunes, L.; Mombach Pinheiro Machado, A.B.; Minuto Paiva, R.; da Silva Menezes, D.; Pires, M.R.; Pires dos Santos, R.; de Souza Kuchenbecker, R.; Barth, A.F. Evaluation of RSV group A and B genotypes among nosocomial and community-acquired pediatric infections in southern Brazil. *Virology Journal* **2014**; 11(36).
21. Vilar-Compte D, Camacho-Ortiz A, Ponce-de-Leon S. Infection Control in Limited Resources Countries: Challenges and Priorities. *Curr Infect Dis Rep* **2017**; 19(5): 20.
22. Reis J, Shaman J. Simulation of four respiratory viruses and inference of epidemiological parameters. *Infect Dis Model* **2018**; 3: 23-34.
23. Bont L. Nosocomial RSV infection control and outbreak management. *Paediatric Respiratory Reviews* **2009**; 10: 16-7.
24. Comas-Garcia A, Aguilera-Martinez JI, Escalante-Padron FJ, Lima-Rogel V, Gutierrez-Mendoza LM, Noyola DE. Clinical impact and direct costs of nosocomial respiratory syncytial virus infections in the neonatal intensive care unit. *Am J Infect Control* **2020**; 48(9): 982-6.
25. Mosalli R, Alqarni SA, Khayyat WW, et al. Respiratory syncytial virus nosocomial outbreak in neonatal intensive care: A review of the incidence, management, and outcomes. *Am J Infect Control* **2021**.
26. French CE, McKenzie BC, Coope C, et al. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. *Influenza Other Respir Viruses* **2016**; 10(4): 268-90.
27. Drysdale SB, Green CA, Sande CJ. Best practice in the prevention and management of paediatric respiratory syncytial virus infection. *Ther Adv Infect Dis* **2016**; 3(2): 63-71.

TABLES AND FIGURES

Figure 1: Flowchart of included nosocomial RSV deaths



Abbreviations: RSV, respiratory syncytial virus.

Figure 2: Location of death for children younger than 5 years with nosocomial RSV-related mortality included in the analysis



Number of included deaths are given for each country (in blue) from which collaborators shared data.

Table 1: Characteristics of children younger than 5 years with nosocomial and community-acquired

RSV-related in-hospital death

	Nosocomial (n=231)	Community-acquired (n=931)	p value
Male sex	107 (46.3)	500 (53.7)	0.05
Age at death (months)	5.4 (2.5-12.1)	6.0 (2.6-13.0)	0.24
Neonatal death	18 (7.8)	38 (4.1)	0.03
<3 months at death	66 (28.6)	244 (26.2)	0.51
<6 months at death	120 (51.9)	452 (48.5)	0.38
Year of death	2012 (2006-2016)	2011 (2006-2015)	0.12
LMIC	32 (13.9)	236 (25.3)	<0.001
UMIC	76 (32.9)	338 (36.3)	0.36
HIC	123 (53.2)	357 (38.3)	<0.001
Comorbidity§	202 (87.4)	527 (56.6)	<0.001
Congenital heart disease	96 (41.6)	209 (22.4)	<0.001
Chronic lung disease	42 (18.2)	112 (12.0)	0.02
Genetic disease	48 (20.8)	134 (14.4)	0.02
Down syndrome	18 (7.8)	47 (5.0)	0.11
Neurological disease	39 (16.9)	135 (14.5)	0.36
Immune disorder	15 (6.5)	31 (3.3)	0.04
Other	68 (29.4)	139 (14.9)	<0.001
Prematurity§	106 (45.9)	225 (24.2)	<0.001
Gestational age (weeks)	36.0 (32.0-38.3); n=174	38.0 (34.0-39.0); n=496	0.004
Birth weight (kgs)	2.5 (1.7-3.1); n=168	2.7 (2.0-3.2); n=449	0.02

Breastfeeding until age \leq 4 months	36/139 (25.9)	161/404 (39.9)	0.003
Length of hospital stay (days)	23.0 (9.8-53.3); n=230	9.0 (4.0-20.0); n=901	<0.001
Intensive care unit (ICU) admission	209/216 (96.8)	641/868 (73.8)	<0.001
Length of ICU stay (days)	14.0 (7.0-30.0); n=194	10.0 (4.0-21.0); n=601	<0.001
Respiratory support	210/210 (100)	685/686 (99.9)	1.00
Mechanical ventilation	186/230 (80.9)	611/902 (67.7)	<0.001
Duration of respiratory support (days)	14.0 (7.0-29.0); n=195	10.0 (4.0-20.0); n=588	<0.001

Data are presented as n (%), n/N (%), or median (IQR). §Considered absent when missing. Abbreviations: LMIC, low-income and lower-middle-income country; UMIC, upper middle-income country; HIC, high-income country.

Figure 3: Age distribution at time of RSV-related nosocomial in-hospital death for children younger than 5 years from low- and middle-income countries (LMIC), upper-middle income countries (UMIC), and high-income countries (HIC)

